Fed. Circ. Won't Block Amgen's Herceptin Biosimilar

Law360
March 6, 2020

The Federal Circuit shot down Genentech's latest attempt to block Amgen from selling a biosimilar version of its blockbuster cancer drug Herceptin. Read more here

Professionals

Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.